Setmelanotide NICE guidance backs NHS funding for Bardet Biedl syndrome from age 6

Setmelanotide NICE guidance published on 3 November 2026 recommends the drug, sold as Imcivree, for obesity and hyperphagia in Bardet-Biedl syndrome in people aged 6 and over. The setmelanotide NICE guidance replaces the institute's earlier advice on the same use, known as HST31, and comes with a confidential NHS discount. For families in England, the key point is money: NICE says the NHS bodies that commission care are responsible for funding a recommended treatment when a doctor and patient choose to use it.

What NICE decided for Bardet Biedl syndrome

The National Institute for Health and Care Excellence, known as NICE, assessed setmelanotide through its highly specialised technologies programme, the route it uses for medicines aimed at very rare conditions. The guidance covers two linked problems in Bardet-Biedl syndrome: obesity and hyperphagia, a hunger that is extreme and hard to control. It applies to people 6 years and over, so both school age children and adults fall inside the wording. NICE says the new document updates and replaces its earlier guidance on setmelanotide for this condition, HST31. The summary published with the decision does not spell out what changed between the two versions, so readers should not assume that any earlier age group, condition or stopping rule has stayed the same or been dropped.

The decision sits beside an older recommendation. NICE already backs setmelanotide for obesity caused by LEPR or POMC deficiency in people 6 years and over, under its highly specialised technologies guidance 21. Those are separate rare genetic causes of obesity, and the new guidance leaves that advice in place. Rhythm Pharmaceuticals, the company behind Imcivree, was the sponsor named on the appraisal. The patient group Bardet-Biedl Syndrome UK, the British Obesity Society, the Royal College of Physicians, NHS England and the Department of Health and Social Care were also listed as stakeholders. The Bristol Technology Assessment Group at the University of Bristol was named as the external assessment group, the independent team that reviews the evidence a company submits.

What the Imcivree discount means for NHS budgets

NICE says a simple discount patient access scheme applies to setmelanotide. Under this kind of scheme the company gives the NHS a fixed reduction on the price, and the size of that reduction is kept confidential. NHS organisations can find the terms on the Commercial Access and Pricing Portal, while organisations outside the NHS are told to contact Rhythm directly. The guidance page does not publish a list price, a discounted price or a yearly cost per patient, and this story does not report one. That means patients, charities and outside analysts cannot check what the NHS will actually spend on each person treated, even though the guidance tells local health bodies they are expected to fund the drug.

NICE says commissioners and providers have a responsibility to provide the funding needed when a health professional and a patient wish to use the treatment, in line with the NHS Constitution.

That funding duty is the practical heart of the decision. NICE says commissioners and providers have a responsibility to provide the funding needed when a health professional and a patient wish to use the treatment, in line with the NHS Constitution. In plain terms, the recommendation is meant to stop a local budget from being the deciding factor for an eligible patient in England. NICE also reminds commissioners of their duties to reduce health inequalities and to avoid unlawful discrimination. The guidance does not remove clinical judgement, however. NICE states that doctors must still take account of each patient's needs, preferences and values, and that the final choice rests with the health professional and the patient or their carer.

How the appraisal reached a decision

NICE's project page shows how the review moved. The topic was marked as selected on 5 November 2025, with NICE giving as its reason that the medicine would matter to patients, carers, professionals and commissioners. A consultation on the remit, draft scope and stakeholder list ran from 1 to 15 December 2025, and invitations to take part went out on 18 December 2025. An earlier version of the page listed a first committee meeting on 25 June 2026 and expected publication on 19 August 2026, both marked provisional. The setmelanotide NICE guidance appeared on 3 November 2026, according to the date on NICE's listing, later than that first schedule had suggested.

The appraisal ran under NICE's standard highly specialised technologies process as project number 6598. No comparator companies were listed on the project page. The Scottish Medicines Consortium, Healthcare Improvement Scotland, the Welsh Government, the NHS Wales Joint Commissioning Committee and the Department of Health in Northern Ireland appeared as general commentators rather than decision makers. NICE guidance applies directly in England, and the other UK nations make or adopt their own funding decisions through separate routes. This story could not confirm how each nation will handle the new advice, so families outside England should ask their specialist team which body decides access where they live and whether a local review is still pending.

What patients and prescribers still do not know

Several practical questions remain open in the public summary. It does not say how many people in England live with Bardet-Biedl syndrome, how many might start treatment, or how quickly NHS services will put the setmelanotide NICE guidance into practice. It does not describe any response test, such as a set change in weight or hunger that a patient must reach to keep receiving the drug. Readers who need those details should check the full recommendation sections on the NICE guidance page, because the summary text available for this story covered the decision, the discount and the funding duty but not the committee's detailed reasoning or the evidence it weighed.

Setmelanotide is a prescription medicine, and NICE's advice concerns its use within the NHS. People taking it, or their carers, can report suspected side effects to the Medicines and Healthcare products Regulatory Agency through the Yellow Card scheme, as NICE asks. The decision stands apart from the wider fight over weight loss injections, where MPs have called the NHS Mounjaro rollout unambitious. In Scotland, a freedom of information survey found only 705 patients treated with those injections on the NHS. Setmelanotide serves a small rare disease group, so its funding route and budget pressures differ from those of drugs aimed at a far larger share of adults.

Conclusion

The setmelanotide NICE guidance gives people aged 6 and over with Bardet-Biedl syndrome a route to NHS funding in England, backed by a confidential discount and a duty on commissioners to pay. What it does not show in public is the price, the number of patients expected or any conditions on continued use. Families should raise the decision with their specialist team and watch how the other UK nations respond.